Invention:
This invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action.
Background:
Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics are associated with a number of side effects including an increased risk of suicidal thoughts in those taking antidepressants. Therefore, a novel pathway is needed for rapid onset with minimal side effects.
Applications:
Advantages:
- Provides a treatment for depressive and anxiety disorders
Status: issued U.S. patent #11,542,302
